Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Capital Employed (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Return on Capital Employed for 15 consecutive years, with 0.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 1.0% year-over-year to 0.05%, compared with a TTM value of 0.05% through Dec 2025, up 1.0%, and an annual FY2025 reading of 0.05%, up 1.0% over the prior year.
  • Return on Capital Employed was 0.05% for Q4 2025 at Amicus Therapeutics, down from 0.05% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.07% in Q1 2025 and bottomed at 0.39% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.17%, with a median of 0.22% recorded in 2023.
  • The sharpest move saw Return on Capital Employed fell -13bps in 2022, then grew 22bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.26% in 2021, then plummeted by -34bps to 0.35% in 2022, then surged by 64bps to 0.13% in 2023, then skyrocketed by 131bps to 0.04% in 2024, then grew by 25bps to 0.05% in 2025.
  • Business Quant data shows Return on Capital Employed for FOLD at 0.05% in Q4 2025, 0.05% in Q3 2025, and 0.03% in Q2 2025.